NCT05891496 - A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

August 19, 2024

Study Completion Date

September 11, 2025

Conditions

Alzheimers Disease

Interventions

DRUG

Semaglutide

Semagllutide will be administered once weekly subcutaneously.

DRUG

Placebo

Placebo matched to semaglutide will be administered once weekly subcutaneously.

Trial Locations (10)

Centre de la Mémoire, Geneva

Rigshospitalet - afsnit 8015, København Ø

Azienda Ospedaliera Spedali Civili di Brescia, Brescia

Brain Matters Research, Delray Beach

Banner Sun Health Research Institute, Sun City

Ottawa Memory Clinic, Ottawa

Memory Program, Toronto

Azienda Ospedaliera di Perugia;Ospedale S. Maria della Miser, Perugia

Fondazione Santa Lucia IRCCS, Roma

Karolinska Universitetssjukhuset, Huddinge, Stockholm